Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benzalkonium chloride

This article was originally published in The Rose Sheet

Executive Summary

FDA should not permit antiseptic ingredient for use in OTC drug products due to a lack of data demonstrating long-term safety, counsel for supplier Lonza's says in an Aug. 3 letter. Responding to a citizen petition filed by International Laboratory Technology Corp. requesting GRAS/E status for the ingredient in OTC topical antimicrobial products, Lonza notes the agency has required data on chronic toxicity for a number of ingredients evaluated in the health care antiseptic drug products monograph, but the studies submitted by ILTC do not address long-term use. FDA currently considers benzalkonium chloride (.11%-.13%) a Category III ingredient (data insufficient to demonstrate safety/efficacy) except for short-term use (1"The Rose Sheet" April 24, p. 9)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS008352

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel